Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations.

Simple item page
dc.contributor.authorColquitt, Charlie
dc.contributor.authorJones, Jocelyn D
dc.contributor.authorJackson, Sylvia H
dc.date.accessioned2015-08-20T08:12:49Z
dc.date.available2015-08-20T08:12:49Z
dc.date.issued2014-10
dc.description.abstractAtrial Fibrillation (AF) is the most common arrhythmia. AF is a major risk factor for stoke. Warfarin has been available for more than 60 years and until recently it was the only oral anticoagulant used for the prevention of stroke. Despite the extensive studies and proven efficacy, its utility is limited by multiple factors. Warfarin interacts with a multitude of drugs and foods, has a delayed onset of action, has a narrow therapeutic range, requires routine lab monitoring and exhibits variable responses in patients. The novel agents dabigatran, rivaroxaban and apixaban have the potential to have some of the limitations of warfarin. This article will discuss the pharmacokinetic and pharmacological considerations and different characteristics of the novel anticoagulants when used for the prevention of AF.en_US
dc.identifier.citationColquitt Charlie, Jones Jocelyn D, Jackson Sylvia H. Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations. Cardiology and Angiology An International Journal. 2014 Oct-Dec: 2(4): 278-292.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/162168
dc.language.isoenen_US
dc.source.urihttps://sciencedomain.org/abstract/5220en_US
dc.subjectNovel anticoagulantsen_US
dc.subjectdabigatranen_US
dc.subjectrivaroxabanen_US
dc.subjectapixabanen_US
dc.subjectdirect thrombin inhibitoren_US
dc.subjectfactor Xa inhibitoren_US
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAnticoagulants --pharmacokinetics
dc.subject.meshAnticoagulants --pharmacology
dc.subject.meshAntithrombins --pharamcokinetics
dc.subject.meshAntithrombins --pharmacology
dc.subject.meshAtrial Fibrillation --drug therapy
dc.subject.meshAtrial Fibrillation --surgery
dc.subject.meshAtrial Fibrillation --therapy
dc.subject.meshBenzimidazoles --pharmacokinetics
dc.subject.meshBenzimidazoles --pharmacology
dc.subject.meshFactor Xa Inhibitors --pharmacokinetics
dc.subject.meshFactor Xa Inhibitors --pharmacology
dc.subject.meshHumans
dc.subject.meshMorpholines --pharmacokinetics
dc.subject.meshMorpholines --pharmacology
dc.subject.meshPyrazoles --pharmacokinetics
dc.subject.meshPyrazoles --pharmacology
dc.subject.meshPyridones --pharmacokinetics
dc.subject.meshPyridones --pharmacology
dc.subject.meshThiophenes --pharmacokinetics
dc.subject.meshThiophenes --pharmacology
dc.subject.meshWarfarin --pharmacokinetics
dc.subject.meshWarfarin --pharmacology
dc.subject.meshbeta-Alanine --pharmacokinetics
dc.subject.meshbeta-Alanine --pharmacology
dc.titleAnalysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
caij2014v2n4p278.pdf
Size:
239.09 KB
Format:
Adobe Portable Document Format
Description:
Original research article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Cardiology and Angiology: An International Journal